ArticleBMC infectious diseases2025
Correlates of virological non-suppression among children and adolescents aged 5-19 years on Dolutegravir-based regimens attending Gulu regional referral hospital, Northern Uganda: a mixed methods cross-sectional study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Dolutegravir-Based Antiretroviral Therapy on Viral Load Suppression and Uptake of DTG-Based Regimen Among Pediatric HIV Patients in Africa: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS CarePooled it
- Efficacy of dolutegravir-based therapy in achieving virological suppression in PLHIV in low- and middle-income countries: real-world evidence from a large clinical cohort in Cameroon.BMC infectious diseases · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundViral suppression has been sub-optimal among children and adolescent in Uganda, despite a near-universal transition to the much effective Dolutegravir-based regimens. Therefore this study was aimed at determining the prevalence of virological non-suppression and its associated correlates among children and adolescents aged 5-19 years on Dolutegravir-based regimens.
methodsA mixed methods cross-sectional study was conducted among 303 children and adolescents aged 5-19 years on Dolutegravir-based regimens from January 2021 to December 2022. The chi-square likelihood ratio test and Modified Poisson regression analyses were used to identify correlates significantly associated with virological non-suppression. Purposive and convenient sampling were done and interviews analyzed using manual thematic content analysis.
resultsVirological non-suppression prevalence was at 12.2% (95% CI: 8.5% - 16.0%). Parental status (being single orphan, adjusted Prevalence Ratio (aPR: 5.4 [95% CI: 1.81-15.90], p = < 0.001), (double orphan, aPR: 3.3 [95% CI: 1.07-10.02], p = 0.04), clinical stage (WHO clinical stage II on Dolutegravir-based anti-retroviral therapy initiation (aPR: 3.4 [95% CI: 1.55-7.62], p = < 0.001), and malnutrition status (moderate acute malnutrition (aPR: 2.3 [95% CI: 1.16-4.76], p = 0.02) were significantly associated with virological non-suppression. Findings also indicated that differentiated service delivery models, multi-month drug dispensing tolerability and palatability of Dolutegravir, adolescent child friendly services, awareness and stigma reduction programs, having a caregiver and having a caregiver who is on anti-retroviral therapy emerged as important deterrents to virological non-suppression. However, HIV status non-disclosure, food unavailability, deprivation of family and social support, secondary school age, poor adherence, malnutrition, depression, tuberculosis co-infection, disease progression to stage II and above, drug holidays and fatigue, transitioning from child to adolescent age and information gap on treatment were potential enablers of virological non-suppression.
conclusionThe prevalence of virological non-suppression among children and adolescents aged 5-19 years on Dolutegravir-based regimens was 12.2%. This was relatively lower in comparison to other studies conducted in Uganda and other Sub-Saharan African countries but short of the UNAIDS third 95% target for viral suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.